How did MRSN's revenue and expenses trend in Q4 2024?

Mersana Therapeutics (MRSN) experienced a revenue of $16.36 million in Q4 2024, with notable expenses in research and development (R&D) and selling, general, and administrative (SG&A) costs:

1. Revenue Stability: The company's revenue remained at $16.36 million, indicating a stable financial performance during the quarter.
2. Increased Costs: The Cost of Goods Sold (COGS) was $22.29 million, which is significantly higher than the revenue. This suggests that MRSN faced challenges in managing its cost of goods sold compared to its revenue generation.
3. R&D Investments: MRSN continued to invest heavily in R&D, with expenses amounting to $8.89 million. This reflects the company's commitment to innovation and development, which is crucial for its long-term growth in the biotech sector.
4. SG&A Expenses: The Selling, General, and Administrative (SG&A) expenses were not provided separately from the COGS, which makes it difficult to assess the specific components of these expenses. However, the total expenses of $22.29 million (COGS + SG&A) indicate that MRSN had substantial overhead costs during the quarter.